LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

October 11, 2005

OVERNIGHT COURIER 10/11/05

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane Room 1061
Rockville, MD 20852

Withdrawal of Citizen Petition
Docket # 2004P-0409/CP 1

Dear Sir or Madam:

Reference is made to the petition submitted on September 8, 2004 pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act and in accordance with 21 CFR 10.30 on behalf of a client requesting the Commissioner of the Food and Drug Administration to declare that the drug product, Metoclopramide Hydrochloride Orally Disintegrating Tablets 5 mg and 10 mg, is suitable for consideration in an abbreviated new drug application (ANDA).

At this time and since a pharmaceutical equivalent of the product requested in this petition has been approved in a 505(b)(2), we request that the petition be withdrawn.

Sincerely,

Robert Pollock

Robert. W. Pollock
Senior Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, New York 11590

RWP/pk

cc: Arianne Camphire (OGD)
Cecelia Parise (OGD)

A31P5284

2004P-0409

WDL 1